8-K: Microbot Medical Completes At-the-Market Offering, Raises $4.8 Million

Microbot Medical has completed its at-the-market offering, raising approximately $4.8 million through the sale of over 4.2 million shares.

Summary

• Microbot Medical has concluded its at-the-market (ATM) offering, selling 4,276,486 shares of common stock.
• The company generated gross proceeds of $4,819,278 from the share sales.
• Placement fees totaled $144,578, with additional offering expenses also incurred.
• The ATM offering was conducted through H.C. Wainwright & Co. LLC, acting as sales agent.
• The company is no longer selling shares under the ATM agreement.
• Following the offering, Microbot Medical has 20,242,119 shares of common stock issued and outstanding.
• Microbot Medical's intellectual property portfolio includes 16 issued/allowed patents and 59 pending patent applications worldwide.
• The company also holds 11 issued/allowed design patents and 3 pending design patents globally.
• Microbot Medical has registered trademarks for its LIBERTY Endovascular Robotic Surgical System, Microbot Medical wordmark and logo, One & Done wordmark, and NovaCross trademark in various regions.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a planned capital raise, which is positive. However, the company is still in a development stage and faces risks, so the sentiment is moderately positive.

Positives

• The successful completion of the ATM offering provides Microbot Medical with approximately $4.8 million in gross proceeds.
• The company has a strong intellectual property portfolio with numerous patents and trademarks.
• The company has a significant number of shares outstanding, indicating a reasonable level of market capitalization.

Negatives

• The company incurred $144,578 in placement fees, reducing the net proceeds from the offering.
• The document does not provide details on the other offering expenses.

Risks

• The company's future financial performance will depend on its ability to commercialize its technology and generate revenue.
• The company's intellectual property may be challenged or infringed upon by competitors.
• The company may need to raise additional capital in the future to fund its operations.

Future Outlook

The company is no longer selling shares under the ATM agreement, and future funding will likely depend on other sources.

Management Comments

• Harel Gadot, Chief Executive Officer, President and Chairman, signed the report on behalf of the company.

Industry Context

The completion of the ATM offering is a common method for biotech companies to raise capital, especially those in the development stage. The focus on intellectual property is typical for companies in the medical device sector.

Comparison to Industry Standards

• The amount raised, $4.8 million, is relatively small compared to larger capital raises by established medical device companies, such as Intuitive Surgical or Medtronic, which often raise hundreds of millions or billions in debt or equity offerings.
• The number of patents and trademarks held by Microbot Medical is significant for a company of its size, indicating a strong focus on protecting its intellectual property, which is comparable to other companies in the medical robotics space such as Stryker or Zimmer Biomet.
• The use of an at-the-market offering is a common practice for smaller companies to raise capital without significant dilution, similar to other small-cap biotech companies.

Stakeholder Impact

• Shareholders have experienced dilution due to the issuance of new shares.
• The company has secured additional funding to support its operations and development.

Key Dates

Keywords

At-the-Market Offering, ATM, Share Issuance, Intellectual Property, Patents, Trademarks, Microbot Medical, LIBERTY Endovascular Robotic Surgical System, Capital Raise, Common Stock